ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by xena555on Jan 05, 2018 8:34am

152 Views

Post# 27287814

licencing deal for Denali

Denali (DNLI-Q) signs deal with Takeda this morning- $150mm up front, combination of $40mm cash, and $110 equity at $26.10- a 62% premium to yesterdays close. Denali is developing three preclinical Alzheimer's drug candidates. Needless to say, some sort of a licensing deal would help draw attention to PMN.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload